Molecular Medicine |
From the Departments of Anesthesiology/Critical Care Medicine (S.R., A.B., H. Kyo Lim, A.C., G.S., H. Kyung Lim, E.B., D.N., D.E.B.), Biomedical Engineering (G. Gupta, J.S., L.S., K.S., E.T., A.S., D.E.B.), Medicine (G. Gerstenblith, H.C.C.), Division of Cardiology, Molecular and Comparative Pathobiology (D.H.), the Johns Hopkins Medical Institutions, Baltimore, Md; Department of Chemistry (M.I., D.W.C.), University of Pennsylvania, Philadelphia; Department of Cardiovascular Medicine (N.J.A.), John Radcliffe Hospital, University of Oxford, UK; and Institute of Long Life, Department of Anesthesiology and Pain Medicine (H. Kyung Lim), Yonsei University Wonju College of Medicine, Wonju, Korea.
Correspondence to Dan Berkowitz, MD, Associate Professor, Anesthesiology/CCM, Tower 711, The Johns Hopkins Hospital, 600 N Wolfe St, Baltimore, MD 21287. E-mail dberkowi{at}bme.jhu.edu
Oxidized low-density lipoproteins increase arginase activity and reciprocally decrease endothelial NO in human aortic endothelial cells. Here, we demonstrate that vascular endothelial arginase activity is increased in atherogenic-prone apolipoprotein E–null (ApoE–/–) and wild-type mice fed a high cholesterol diet. In ApoE–/– mice, selective arginase II inhibition or deletion of the arginase II gene (Arg II–/– mice) prevents high-cholesterol diet–dependent decreases in vascular NO production, decreases endothelial reactive oxygen species production, restores endothelial function, and prevents oxidized low-density lipoprotein–dependent increases in vascular stiffness. Furthermore, arginase inhibition significantly decreases plaque burden. These data indicate that arginase II plays a critical role in the pathophysiology of cholesterol-mediated endothelial dysfunction and represents a novel target for therapy in atherosclerosis.
Key Words: vascular stiffness eNOS uncoupling pulse wave velocity nitric oxide L-arginine
Related Article:
Circ. Res. 2008 102: 866-868.
This article has been cited by other articles:
![]() |
J. H. Kim, L. J. Bugaj, Y. J. Oh, T. J. Bivalacqua, S. Ryoo, K. G. Soucy, L. Santhanam, A. Webb, A. Camara, G. Sikka, et al. Arginase inhibition restores NOS coupling and reverses endothelial dysfunction and vascular stiffness in old rats J Appl Physiol, October 1, 2009; 107(4): 1249 - 1257. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Jung, A. T. Gonon, P.-O. Sjoquist, J. O. Lundberg, and J. Pernow Arginase inhibition mediates cardioprotection during ischaemia-reperfusion Cardiovasc Res, September 18, 2009; (2009) cvp303v2. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sankaralingam, H. Xu, and S. T. Davidge Arginase contributes to endothelial cell oxidative stress in response to plasma from women with preeclampsia Cardiovasc Res, September 3, 2009; (2009) cvp277v2. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Zhang, B. Baban, M. Rojas, S. Tofigh, S. K. Virmani, C. Patel, M. A. Behzadian, M. J. Romero, R. W. Caldwell, and R. B. Caldwell Arginase Activity Mediates Retinal Inflammation in Endotoxin-Induced Uveitis Am. J. Pathol., August 1, 2009; 175(2): 891 - 902. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Hughes, O. Wirth, K. Krajnak, R. Miller, S. Flavahan, D. E. Berkowitz, D. Welcome, and N. A. Flavahan Increased Oxidant Activity Mediates Vascular Dysfunction in Vibration Injury J. Pharmacol. Exp. Ther., January 1, 2009; 328(1): 223 - 230. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Santhanam, D. W. Christianson, D. Nyhan, and D. E. Berkowitz Arginase and vascular aging J Appl Physiol, November 1, 2008; 105(5): 1632 - 1642. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. Vanhoutte Arginine and Arginase: Endothelial NO Synthase Double Crossed? Circ. Res., April 25, 2008; 102(8): 866 - 868. [Full Text] [PDF] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2008 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |